Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 2/20 | 0.55 |
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
| ▸ | MC4R | P32245 | 8/20 | 0.53 |
| ▸ | MC5R | P33032 | 8/20 | 0.53 |
| ▸ | MC3R | P41968 | 8/20 | 0.53 |
| ▸ | MC1R | Q01726 | 8/20 | 0.53 |
| ▸ | NNMT | P40261 | 1/20 | 0.48 |
| ▸ | GRB7 | Q14451 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | TSLP | Q969D9 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14817105 | 0.95 | CTSG (0.55) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL14096826 | 0.93 | CTSG (0.59) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL14137295 | 0.93 | CTSG (0.54) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL13659870 | 0.92 | CTSG (0.59) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL12837665 | 0.90 | CTSG (0.51) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL13656565 | 0.90 | CTSG (0.51) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL14962605 | 0.89 | MC4R (0.54) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL14096946 | 0.89 | MC4R (0.59) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL14107743 | 0.88 | TSLP (0.54) | CTSGMC4RMC5RMC3RMC1R | |
| SCHEMBL22382215 | 0.88 | TSLP (0.54) | CTSGMC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404802-B2 | a targeting vector which binds to receptors associated with integrin receptors, angiogenesis; contrast agents; diagnosis of malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma | GE HEALTHCARE AS (NO) | 2013-03-26 | — | — | US | disclosed |
| US-20080187493-A1 | a targeting vector which binds to receptors associated with integrin receptors, angiogenesis; contrast agents; diagnosis of malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma | GE HEALTHCARE AS (NO) | 2008-08-07 | — | — | US | disclosed |
| US-7351790-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187493-A1 | a targeting vector which binds to receptors associated with integrin receptors, angiogenesis; contrast agents; diagnosis of malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma | KDR, VCAM1, FLT1 | CTSG 887/4885PLAU 857/4885MC4R 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.